AfaSci

Focus: AfaSci is a small molecule biotech company focused on neurology, currently advancing a lead asset (AFA-281) through early-stage clinical development in alcohol use disorder, neuropathic pain, and related conditions. The company is pre-revenue and operates from Redwood City, CA.

Neurology

Profile data last refreshed 9h ago · AI intelligence enriched 2w ago

Open Jobs

About AfaSci

AI assessmentNot Hiring

No open roles listed right now. Follow AfaSci to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AFA-281 is a small molecule, orally available

Alcohol

Phase 1

Clinical Trials (1)

NCT06719908A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers

Phase 1

Help build intelligence for AfaSci

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to own significant program roles on a focused, early-stage asset with multiple Phase 1/2 indications in high-unmet-need areas (alcohol use disorder, neuropathic pain).
Small molecule platform in neurology offers hands-on exposure to drug discovery, early clinical development, and regulatory strategy across multiple indications.
Seed-stage environment enables rapid skill-building and cross-functional impact before scale-up complexity.

Watch Out For

Zero active job openings at time of data snapshot—hiring posture is not actively growing, indicating potential early-stage cash constraints or focused team model.
Pre-revenue status with no disclosed funding, cash position, or financials creates uncertainty around runway, future financing, and salary competitiveness.
Only 4 trials across Phase 1/2 with no Phase 3 programs means catalysts are years away; early-stage execution risk is high.

Generated by Claude from AfaSci's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AFA-281

Pain, Neuropathic

Phase 1

Clinical Trials (1)

NCT05547503Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers

Phase 1

AFA-281

Alcohol Abuse

Phase 2

Clinical Trials (1)

NCT06710431A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

Phase 2

AFA-281

Lumbosacral Radiculopathy

Phase 2

Clinical Trials (1)

NCT06649747Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

2 pipeline

Marketed

Pipeline